Again, it is noteworthy that the rate of secondary infections tended to increase in the group treated with anti-IL-6 signaling agents compared to the SOC group in patients with critical disease (pooled OR = 1.85, 95% CI 0.95–3.61, p = 0.07), despite not reaching statistical difference (Figure 6). This evidence concerns the gene IL6 and infection.